Trial NC-HEM-07-5

A Double-Blind, Placebo-Controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, a Thrombopoietin Receptor Agonist, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who are Not Candidates for Anti-Viral Treatment with Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia.

Type: Non-Cancer Related; Therapeutic
Phase: Phase II
Status: Open to Accrual
Treatments: Biological Response Modifier
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Howard Liebman, M.D.
Other Trial Staff: Laurie Hornor, R.N., Melissa Peralta, D.M.

Staff may log in to see study documents.

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.